J Anthony Child

Summary

Affiliation: St James's University Hospital
Country: UK

Publications

  1. ncbi request reprint High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
    J Anthony Child
    Academic Unit of Haematology and Oncology, Cancer Research United Kingdom Clinical Centre, University of Leeds, Leeds, United Kingdom
    N Engl J Med 348:1875-83. 2003
  2. ncbi request reprint Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation
    Andy C Rawstron
    Academic Unit of Haematology and Oncology, Algernon Firth Building, University of Leeds, Leeds LS1 3EX, UK
    Blood 100:3095-100. 2002
  3. ncbi request reprint Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma
    Ranjit K Dasgupta
    Academic Unit of Hematology and Oncology, University of Leeds, United Kingdom
    Blood 102:2345-50. 2003
  4. doi request reprint Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study
    Andy C Rawstron
    St James s University Hospital, Leeds, United Kingdom
    J Clin Oncol 31:2540-7. 2013
  5. ncbi request reprint Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism
    James A L Fenton
    Academic Unit of Haematology and Oncology, Algernon Firth Building, University of Leeds, Leeds LS2 9JT, UK
    Oncogene 22:1103-13. 2003
  6. ncbi request reprint Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
    Brian G M Durie
    Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA, USA
    Hematol J 4:379-98. 2003
  7. ncbi request reprint Future directions in multiple myeloma treatment
    J Anthony Child
    General Infirmary and University of Leeds, Leeds, UK
    Acta Haematol 114:8-13. 2005
  8. ncbi request reprint Home care versus hospital care in patients with multiple myeloma treated with pamidronate
    Alastair G Smith
    Southampton General Hospital, Southampton SO16 0YD, UK
    Int J Palliat Nurs 10:144-9. 2004
  9. ncbi request reprint Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party
    Bradley M Augustson
    Department of Immunology and Cancer Research United Kingdom Clinical Trials Unit, The University of Birmingham, Birmingham, United Kingdom
    J Clin Oncol 23:9219-26. 2005
  10. ncbi request reprint Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials
    Mark Drayson
    Division of Immunity and Infection, Medical School, University of Birmingham, Vincent Drive, Birmingham B15 2TT, United Kingdom
    Blood 108:2013-9. 2006

Collaborators

Detail Information

Publications12

  1. ncbi request reprint High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
    J Anthony Child
    Academic Unit of Haematology and Oncology, Cancer Research United Kingdom Clinical Centre, University of Leeds, Leeds, United Kingdom
    N Engl J Med 348:1875-83. 2003
    ..In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited...
  2. ncbi request reprint Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation
    Andy C Rawstron
    Academic Unit of Haematology and Oncology, Algernon Firth Building, University of Leeds, Leeds LS1 3EX, UK
    Blood 100:3095-100. 2002
    ..036). Analysis of normal and neoplastic plasma cell levels is more sensitive than immunofixation and can identify which patients may benefit from additional treatment strategies at an early stage after transplantation...
  3. ncbi request reprint Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma
    Ranjit K Dasgupta
    Academic Unit of Hematology and Oncology, University of Leeds, United Kingdom
    Blood 102:2345-50. 2003
    ..No difference in outcome by genotype was found for patients treated with high-dose therapy. However, the progression-free survival advantage of the high-dose arm was seen only in patients homozygous for 105Ile (P =.008)...
  4. doi request reprint Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study
    Andy C Rawstron
    St James s University Hospital, Leeds, United Kingdom
    J Clin Oncol 31:2540-7. 2013
    ..To investigate the prognostic value of minimal residual disease (MRD) assessment in patients with multiple myeloma treated in the MRC (Medical Research Council) Myeloma IX trial...
  5. ncbi request reprint Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism
    James A L Fenton
    Academic Unit of Haematology and Oncology, Algernon Firth Building, University of Leeds, Leeds LS2 9JT, UK
    Oncogene 22:1103-13. 2003
    ....
  6. ncbi request reprint Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
    Brian G M Durie
    Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA, USA
    Hematol J 4:379-98. 2003
    ..2. Staging and prognostic factors. 3. Frontline therapy. 4. High-dose therapy and transplant. 5. Maintenance therapy. 6. Supportive care and management of specific complications. 7. Novel therapies and new technologies...
  7. ncbi request reprint Future directions in multiple myeloma treatment
    J Anthony Child
    General Infirmary and University of Leeds, Leeds, UK
    Acta Haematol 114:8-13. 2005
    ..The use of genetic profiles to further delineate groups for different treatment approaches should enable the introduction of patient-specific treatment programmes in the future...
  8. ncbi request reprint Home care versus hospital care in patients with multiple myeloma treated with pamidronate
    Alastair G Smith
    Southampton General Hospital, Southampton SO16 0YD, UK
    Int J Palliat Nurs 10:144-9. 2004
    ..Extra nursing specialist time was required for home therapy. Home therapy with pamidronate in patients with multiple myeloma appeared feasible and safe and was preferred by patients in this study...
  9. ncbi request reprint Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party
    Bradley M Augustson
    Department of Immunology and Cancer Research United Kingdom Clinical Trials Unit, The University of Birmingham, Birmingham, United Kingdom
    J Clin Oncol 23:9219-26. 2005
    ..We have studied early deaths in a series of large multicenter trials to assess direct causes of death, their predictability, and whether current management strategies have reduced their frequency...
  10. ncbi request reprint Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials
    Mark Drayson
    Division of Immunity and Infection, Medical School, University of Birmingham, Vincent Drive, Birmingham B15 2TT, United Kingdom
    Blood 108:2013-9. 2006
    ..The worse survival of IgA patients was attributed to shorter progression-free survival (median, 1.2 vs 1.6 years; P < .001), which is important for maintenance therapy...
  11. ncbi request reprint CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy
    Andy C Rawstron
    Haematologica 91:1577-8. 2006
    ..The data suggest that myeloma plasma cells are unlikely to be depleted by alemtuzumab in most patients...
  12. ncbi request reprint International staging system for multiple myeloma
    Philip R Greipp
    Mayo Clinic College of Medicine and Eastern Cooperative Oncology Group, Rochester, MN, USA
    J Clin Oncol 23:3412-20. 2005
    ..There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification...